Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 6—June 2019
Research Letter

Absence of Neospora caninum DNA in Human Clinical Samples, Spain

Rafael Calero-BernalComments to Author , Pilar Horcajo, Marta Hernández, Luis Miguel Ortega-Mora, and Isabel Fuentes
Author affiliations: Complutense University of Madrid, Madrid, Spain (R. Calero-Bernal, P. Horcajo, L.M. Ortega-Mora); Carlos III Institute of Health, Madrid (M. Hernández, I. Fuentes)

Main Article


Types of samples analyzed and demographic and clinical data for 600 patients tested for Neospora caninum parasites, Spain*

Native country
Spain 382 (63.7)
Other† 36 (6.0)
182 (30.3)
Patient clinical information
Immune status
Immunocompetent 458 (76.3)
Immunodepressed or 
immunosuppressed 83 (13.8)
HIV/AIDS 19 (22.9)
Chemotherapy 29 (34.9)
Organ transplant 35 (42.2)
Unknown 59 (9.8)
Pregnancy-related disorders 454 (75.7)
Seroconversion–infection suspicion 
and lymphadenopathy 418 (92.1)
Spontaneous abortion 27 (5.9)
Ophthalmic 4 (0.9)
Other fetal signs‡ 5 (1.1)
Neurologic and ocular symptoms and 
conditions§ 108 (18.0)
Neurologic condition with ocular signs 8 (7.4)
Ophthalmic only 3 (2.7)
General signs, n = 38 38 (6.3)
Pneumonia 24 (63.2)
Lymphadenopathy 2 (5.3)
Hematologic or oncologic 12 (31.6)

*Patients were from 12 regions: Andalusia, Aragon, Asturias, Balearic Islands, Cantabria, Castile-La Mancha, Castile and Leon, Extremadura, Galicia, Madrid, Navarre, Valencia.
†Africa, 8; Asia, 1; Europe, 8; Latin America, 19.
‡Anencephaly, malformations, and microcephaly.
§Neurologic symptoms and conditions include ataxia, disorientation, sudden blindness, encephalitis, calcifications, and intracranial space occupying lesions; ophthalmic symptoms and conditions include chorioretinitis, panuveitis, posterior uveitis, and vitritis.

Main Article

Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.